Sign inJoin waitlistJoin the waitlist

Van Morris

, Associate Professor, Gastrointestinal Medical Oncology · University of Texas M D Anderson Cancer Center

Credentials: · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas Health Science Center at Houston
2014–2015
Hematology and Medical Oncology
University of Texas Health Science Center at Houston
2011–2014
Internal Medicine
Duke University Hospital
2008–2009
University of Tennessee College of Medicine
2004–2008

Research

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
New England Journal of Medicine · 2019 · 1,180 citations
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
Journal of Clinical Oncology · 2015 · 567 citations
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Systematic review or meta-analysis · Journal of Clinical Oncology · 2023 · First of 21 authors · 549 citations

Scott Kopetz
74 papers
Michael Overman
50 papers
Cathy Eng
46 papers
Arvind Dasari
41 papers
Kanwal Raghav
39 papers
Bryan Kee
34 papers
Robert Wolff
30 papers
Christine Parseghian
27 papers · 2 as a fellow
BJ
Benny Johnson
25 papers
Dipen Maru
20 papers
Emma Holliday
19 papers
Jason Willis
19 papers · 1 as a fellow

Grants

Multi-Omic Liquid Biopsy Assessment in NCI Trials: Evaluating ctDNA, Extravesicle RNA, and Outcomes with Immunotherapy in Patient with Colorectal and Anal Cancers
National Cancer Institute · R50
Contact PI · $544.9K · University of Tx Md Anderson Can Ctr
2024–2029

Clinical trials

Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum
Principal investigator · Not yet recruiting · Phase 2
M.D. Anderson Cancer Center
2026–2033
A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
Principal investigator · Withdrawn · Phase 1, Phase 2
M.D. Anderson Cancer Center
2025–2026
Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2024–2028
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2022–2027